News & Updates

A longitudinal national database study of patients with inflammatory bowel disease (IBD) has identified several risk factors for the development of prostate cancer (PC), including age, obesity, diabetes, married status, family history of PC, and African American race.

Patients with inflammatory bowel disease (IBD) report that the COVID-19 pandemic is a “major concern” for them, reveals a study, noting that the cumulative prevalence is low in this cohort. At-risk patients must be identified and counseled individually.

The Pfizer-BNT162b2 vaccine for the coronavirus disease 2019 (COVID-19) effectively reduces the risk of serious outcomes and hospitalization in patients with inflammatory bowel diseases (IBD), though with slight variance in effectivity with respect to ongoing medications, reports a Qatar study presented at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

A recent systematic review and meta-analysis has found that more than one in five patients develop postinfection irritable bowel syndrome (PI-IBS) following Clostridioides difficile infection (CDI).

The COVID-19 pandemic has contributed to self-reported increases in psychological distress and gastrointestinal symptoms among individuals with irritable bowel syndrome (IBS) and comorbid anxiety and/or depression, reveals a study.